chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt had initial erythematous reaction placed in VAERS form E-24559 and treated with Benadryl and proper site care. Pt did well and erythema and induration resolved. However, aprox 5 days later, the patient started having a vesicular reaction that he initially thought was chiggers. Pt presented to clinic 2 days later with a chief complaint of chiggers and was diagnosed with eczema vaccinatum. Pt was treated with high dose steroids that has stopped further vesicular eruptions.
COVID + 4 days PTA. Admit for COVID pna. Fully vaccinated 1/2021. Steroids, remdesivir, lovenox, cefepime, singulair, toci, zinc. Intubated and with new onset Afib. Developed fevers and secondary bacterial pna. Acute hypoxic respiratory failure due to Covid 19 pneumonia- s/p mechanical intubation but ultimately expired
I had serious side effects after being injected with Shingrix 50mcg/0.5ML SUSR on 10/28/2020 at 3 PM. This is the first of two shots of Shingrix. Starting at 4AM on 10/29/2020 I was awakened with sever shivering and felt very cold! From that point I felt like I had the worst flu like symptom that I have ever had!! The symptoms included hot and cold episodes, painful joints, muscle pain, fatigue, lack of focus, and headache! Felt very feverish the whole time. Although my fever was the highest at 99.7 at 10AM. I had a virtual visit with my Dr. at 11 AM. He suggested a pain and fever reliever and to get a Covid 19 test. I took Aleve 220 gm two times that day. By 8PM on 10/29/20 I felt better. My temp was 97.9. I was tested for Covid at 7AM on 10/30/20 and the results on 10/31/20 were negative. My question to you is...should I now take the next Shingrix shot in a few months?
Headache, Fever, fatigue, pain and redness at injectin site Narrative:  Other Relevant History:
1st dose 14Feb2022, no 2nd dose yet; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 14th February 2022, batch number D4CZ3, expiry date 10th February 2023).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Linked case(s) involving the same patient:  US2023021233   Additional Information: GSK Receipt Date: 09-FEB-2023 Reporter's Comments:  The patient reported that she was not received the second dose of Shingrix yet.  The first dose was on 14th February 2022. The reporter declined to provide more information.  Consumer disconnected call when offered to transfer.  The reporter stated she already spoke with agency, so this had already reported.  A pharmacist called to asked for information regarding patient who received the first dose of Shingrix and never got the second dose.  The pharmacist asked if patient could receive the second dose of Shingrix or if the patient had to start over with vaccination.  No other information was provided.  The reporter was consent to follow-up. Additional Supportive Information: Till the time of reporting the patient did not receive 2nd dose of vaccine, which led to incomplete course of vaccination.
The pt developed a sudden onset of inconsolable screaming, lasting about 6 hours, post vax. This has persisted about 16-18 hours. He has been given Tylenol every 4 hours. He is otherwise normal today (12/5/01).
body aches; Joint pain; nausea; Initial information received on 04-Nov-2019 regarding an unsolicited valid non-serious case received from a physician.  This case involves a male patient who of an unknown age who experienced joint pain (arthralgia), nausea (nausea) and body aches (pain), while he received vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included TUBERCULIN PPD (TUBERCULIN PPD) for Tuberculin test.  On 29-Oct-2019, the patient received a 0.5 mL dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE lot U6321AA expiry date: 21-Jun-2020 via intramuscular route in the left deltoid.  On 29-Oct-2019, the patient developed a non-serious joint pain (arthralgia), nausea (nausea) and body aches(pain) on same day following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE.  Final diagnosis was body aches, nausea and joint pain.  The patient was treated with Paracetamol (Tylenol) for pain.  The outcome of the events was Unknown.
Presented to abdominal pain with the 1 day history of epigastric abdominal pain.  She was tested COVID 19 positive in the ED but asymptomatic.
child developed h/a, fever, stomach ache, fatigue aand weakness - 1 episode of vomiting
Large, local reaction to DPAT left arm 9 x 11 cm induration, erythema, pain.
Immediately I had the sore arm and nausea. It went into having a fever and severe joint pain. The sore arm was for about a day or two but the joint pain was really really bad. I also had some stomach pain. It almost felt like the flu. I have a number or disorders so I not sure, but the doctor did inform me that it could be because the vaccination works through the parts of the gut that I had removed a decade ago.
Information has been received from a physician concerning a 12 month old female who on 27FEB2004 was vaccinated with a subcutaneous dose of varicella vaccine, 0.5ml/once. There was no concomitant medication. On 08MAR2004, 9 days later, the patient broke out with chickenpox, less than 30 lesions. There were no diagnostic laboratory tests performed. There was no treatment required. Unspecified medical attention was sought. There was no product quality complaint involved. Additional information has been requested.  Follow up information has been received from a physician concerning a 12 month old female patient with no relevant meddical history who on 2/27/2004 was vaccinated with a subcutaneous dose of varicella virus vaccine live 0.5 ml. An illness at the time of vaccination was bilateral otitis media with effusion. On 3/08/2004, 9 days later, the patient broke out with chickenpox. Subsequently, the patient recovered. No further information is expected.
this is the pharmacy that fills Imatinib for the pt reporting this AE. pt reported the day after the vaccination she had watery frequent dirrhea the whole day (Saturday). got better on Sunday but upon taking her Imatinib dose she threw up and couldn't take it again that day. pt is improving currently and she had never had that experience with Imatinib alone in the past.
Began having skin itching allover body this morning, and then my lungs itched, and then my tongue began itching. I thought I was having an allergic reaction to something other than the vaccine so I took benedryl. My arm has continued to hurt all day but I only noticed this evening around 8 pm that I had a large red oval (bigger than a grapefruit) rash surrounding my injection site. It's hot to the tough and I think it's swollen.
tripped and fell; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable consumer or other non hcp. A 74-years-old female patient(age at vaccination:74years) received first dose bnt162b2 (BNT162B2,Solution for injection,Batch/Lot number was not reported) via an unspecified route of administration in Arm Left on 01Feb2021 15:00 as 1ST DOSE,SINGLE for covid-19 immunisation.Medical history included fibromyalgia from an unknown date and unknown if ongoing Verbatim Fibromyalgia , arthritis from an unknown date and unknown if ongoing Verbatim Arthritis , eye irritation from an unknown date and unknown if ongoing , pruritus from an unknown date and unknown if ongoing ,fungal infection from an unknown date and unknown if ongoing , asthma from an unknown date and unknown if ongoing , insomnia from an unknown date and unknown if ongoing , irritable bowel syndrome from an unknown date and unknown if ongoing  Why was the patient taking Concomitant Products Omeprazole (Verbatim) Irritable bowel syndrome and gastroparesis , impaired gastric emptying from an unknown date and unknown if ongoing Why was the patient taking Concomitant Products Omeprazole (Verbatim) Irritable bowel syndrome and gastroparesis , pain from an unknown date and unknown if ongoing Why was the patient taking Concomitant Products hydrocodone/acetaminophen (Verbatim) bloody pain. Concomitant medications included trazodone (TRAZODONE) taken for insomnia from 2000 and ongoing; zolpidem (ZOLPIDEM) taken for insomnia from an unspecified start date and ongoing; omeprazole (OMEPRAZOLE) taken for irritable bowel syndrome, impaired gastric emptying from an unspecified start date and ongoing; salbutamol sulfate (ALBUTEROL SULFATE) taken for asthma from an unspecified start date and ongoing; hydrocodone bitartrate, paracetamol (HYDROCODONE/ACETAMINOPHEN) taken for pain from 2005 and ongoing; pregabalin (LYRICA) taken for fibromyalgia from an unspecified start date and ongoing; clotrimazole (CLOTRIMAZOLE) taken for fungal infection from 2018 and ongoing; triamcinolone acetonide (TRIAMCINOLONE ACETONIDE) taken for pruritus from an unspecified start date and ongoing; fluorometholone (FLUOROMETHOLONE) taken for eye irritation from an unspecified start date and ongoing. The patient underwent lab tests and procedures which included weight overweight on unspecified date, weight105lbs on Thirty three years ago she weighed 105lbs,weight: gained weight on unspecified date. She has gained weight and gets yeast infections under her breast and tummy.The patient experienced nausea, vomiting on 01Feb2021, diarrhoea on 01Feb2021, tripped and fell on 04Feb2021.The outcome of the events nausea, vomiting, diarrhoea was not recovered and the outcome of the event of fall was recovered. Follow-up attempts completed. No further information expected.
A report has been received from a Health Professional via medical representative concerning a 29 year old male patient. The follow up was received from consumer via spontaneous source. The patient's medical history included wheezing in Jan-2009 and the patient was treated for borderline bronchitis in Jan-2009. The patient's concomitant medications were not provided. The patient received nasal FLUMIST started during Dec-2011. It was reported that the patient was treated for wheezing in Jan-2009, he received FLUMIST in Dec-2011 and Jan-2012 he experienced wheezing (Preferred Term: Wheezing) two weeks later. It was also reported that there have been at least 5 elementary aged patients in the past two years and have come into the office to get treated for wheezing after having received the FLUMIST. The patient's wife submitted the questionnaire. It was reported that the patient had coughing and chest tightness during the event. He was medically attended and the episode was managed by breathing treatments 3-4 daily for 1 week. The patient had given antibiotics and robitussin AC. The event lasted for 1 week. The symptoms resolved with the treatment. The patient recovered from the event of wheezing on an unspecified date. The reporter assessed the event of wheezing to be non-serious.
Flushing, itching, wheezing.  All within 40 min of shot. Wheezing continues 7 days post vaccine.
tiredness and a sore arm; tiredness and a sore arm; felt electrified; could not sleep; there may be an interaction between Tenvir and he Pfizer covid-19 vaccine.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hepatitis B" (unspecified if ongoing), notes: history of hepatitis B and takes Tenvir daily as treatment. Concomitant medication(s) included: TENVIR taken for hepatitis b. The following information was reported: FATIGUE (non-serious), PAIN IN EXTREMITY (non-serious), outcome "unknown" and all described as "tiredness and a sore arm"; ELECTRIC SHOCK SENSATION (non-serious), outcome "unknown", described as "felt electrified"; INSOMNIA (non-serious), outcome "unknown", described as "could not sleep"; DRUG INTERACTION (non-serious), outcome "unknown", described as "there may be an interaction between Tenvir and he Pfizer covid-19 vaccine.".  Additional information:She stopped taking Tenvir for a couple of day and then felt normal again. However, when she resumed Tenvir, she again experienced the electrified feeling and not being able to sleep. She stopped Tenvir for the second time and reports only taking two tablets of Tenvir since getting the Pfizer covid-19 vaccine injection. The consumer suspected there may be an interaction between Tenvir and he Pfizer covid-19 vaccine. The consumer is scheduled to receive her second injection of the Pfizer covid-19 injection today since it has been 3 weeks since the first injection.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Her fiance received the first dose on 24Aug2021 and had a headache after this that she still has from the first dose; This is a spontaneous report from a contactable consumer. A 44-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection) via an unspecified route of administration on 24Aug2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date it was reported as patient received her first dose on 24Aug2021 and had a headache after this that she still has from the first dose. The seriousness of the event was non-serious. The outcome of event was unknown.  The lot number for BNT162b2 was not provided and will be requested during follow up.
1 day after vaccine was administered patient started to feel fatigue and stiff neck 2 days after vaccine started to feel nauseous and mild dizziness. Treat with Meclizine 25 mg for the dizziness.
Large,  round, hard, red, itchy, welt at injection site. Apparently 4 inches in diameter
site of injection - pruritis, headache, insomnia, pruritic macular erythematous rash on face neck trunk and arms, near syncope, fatigue, sore throat, ear ache, fever-subjective, joint aches, nausea, vomiting, malaise
This spontaneous report was received from a medical assistant (clinical coordinator) and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was provided. On an unknown date in 2017, between 27-JUL-2017 and 03-AUG-2017, the patient was vaccinated with improperly stored dose of VARIVAX injection (lot # reported as N008077; expiration date: 09-MAR-2019; dose and route of administration were not reported). Concomitant therapy included properly stored sterile diluent (MERCK) injection. The reporter stated that the administered dose of VARIVAX was stored at temperature of -10.7 degrees Celsius for 2 hours 10 minutes. Data logger was used to detect temperature excursions. There were no previous temperature excursions reported. No adverse effects were reported. No product quality complaint was involved. This is one of seven reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1708USA005837: US-009507513-1708USA005841: US-009507513-1708USA005839: US-009507513-1708USA005840: US-009507513-1708USA005836: US-009507513-1708USA003358.
Ringing in the ears started on 03/29/2021. Left ear was predominantly louder. Extreme imbalance started shortly after. Both got increasingly worse causing (2) hospital visits. Second visit I was admitted for a two day period 5/25/21 to 5/26/21. Imbalance has improved considerably. Ringing still persist.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. ON 25-AUGF-2015, the patietn was vaccinated with expired (Oka/Merck) VARIVAX (lot # J009989) 0.5 ml once, subcutaneous. No adverse events were reproted. No further information available. Additional information has been requested.
Very sore arm 8 hours after injection. Chills, body aches and nausea 8 hours later than lasted a full day. Extreme fatigue for 24 hours.
hot sweats; not feeling well; threw up one episode; Chills; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (hot sweats), MALAISE (not feeling well), VOMITING (threw up one episode) and CHILLS (Chills) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036B21A and 044A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Apr-2021, the patient experienced HYPERHIDROSIS (hot sweats), MALAISE (not feeling well), VOMITING (threw up one episode) and CHILLS (Chills). At the time of the report, HYPERHIDROSIS (hot sweats), MALAISE (not feeling well), VOMITING (threw up one episode) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information as not reported. concomitants - Blood pressure Medication
small red area on my arm that I had my shot on, not at the same spot as shot, small red rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (small red area on my arm that I had my shot on, not at the same spot as shot, small red rash) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (small red area on my arm that I had my shot on, not at the same spot as shot, small red rash). At the time of the report, RASH ERYTHEMATOUS (small red area on my arm that I had my shot on, not at the same spot as shot, small red rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were not reported. No treatment medications were not provided.
Fever - Information has been received from a health professional concerning her 5 year old male nephew with a history of attention deficit disorder and allergies to methylphenidate HCL ritalin and dextroamphetamine - amphetamine asparate - amphetamine sulfate - adderall. The patient was vaccinated with his first and second dose  of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live second generation before his first birthday in approximately 1995.  He received the third dose between October 2000 and  Decoember 2000.  The reporter stated that twelve days after receiving his third vaccination her nephew had a fever of 104 degrees fahrenhelt.  The patient did not receive medical attention.  The school district  wanted the child to receive a fourth dose. F/U 6/19/02 indicated that the pt was vaccinated with the 3rd dose of MMRII in 12/00. There was no illness at the time of vaccination. About 14 days after the injection on 12/26/00, he developed a temperature of 104F. The physician was called and since the pt had "no other symptoms of a URI, etc, the temperature was attributed to the MMR". It was reported that the pt required a doctor visit. The school district wanted the child to receive a 4th dose, however the dose was never given. Additional info has been requested.
headache; constipation; This is a spontaneous report from a contactable other HCP. A 30-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EK9231), intramuscular in left arm on 23Dec2020 at a single dose for covid-19 vaccination. The vaccine was administered in the workplace clinic. The patient's medical history and concomitant medications were not reported. The patient had no known allergies. The patient was not pregnant. On 24Dec2020, the patient experienced constipation and headache since vaccine (7 days). The outcome of the events was unknown. There was no treatment for the events. ON 24Dec2020, the patient had COVID test type post vaccination=Nasal Swab with a negative result. The events were assessed as non-serious.
Woke up at 1am with chills and a fever I didn't check my fever until I woke again at 3:30am with headaches and nausea at which point my fever was  measuring every hour between 101 and 104.5F at which point I took an OTC tylenol which lowered my fever to 98F. I had to take the tylenol every 4 hours to keep my temp below 100 until that evening. Chills persisted until the following afternoon and the headaches ended the day after that.
Patient received expired Fluzone (6/30/21) and has not returned for new dose.
Moderna COVID-19 Vaccine EUA 8 days after receiving the vaccine, the arm I received it in started to itch. There was a rash and red oval shape. Following me scratching my arm, the rash spread to other parts of my body, including sides, other arm, and ears, but mostly on my hands. My hands have had intense itching.
Site: Pain at Injection Site-Medium, Systemic: Body Aches Generalized-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Unable to Sleep-Medium
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in 2023 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid from 29Sep2023 to 04Oct2023.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300322300 same patient, different drugs and events;
pt came by amb p/tonic clonic sz;no sz activity p/arrival to hosp;
She got the vaccine, she felt tired, had a bit of a headache, and felt like lying down.  Then the next day started with really bad joint pain, stiffness and swelling in her joints, fingers, pretty much all her joints, as well as her back, knees and hips.  There were a couple of nights that it kept her awake.   She is still having some joint pains, but did not have these pains prior to the vaccine, possibly some arthritis but not to this extent.  Right now it hurts her hands to squeeze them together and close them.  She has been taking Tylenol for these symptoms, as well as Advil.